Pyxis Oncology (PYXS) Competitors $1.28 -0.08 (-5.88%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.29 +0.01 (+0.78%) As of 02/21/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PYXS vs. CRVS, TRVI, CMPS, AQST, GOSS, CADL, ATYR, IMMP, OLMA, and KRROShould you be buying Pyxis Oncology stock or one of its competitors? The main competitors of Pyxis Oncology include Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), COMPASS Pathways (CMPS), Aquestive Therapeutics (AQST), Gossamer Bio (GOSS), Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), Olema Pharmaceuticals (OLMA), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Pyxis Oncology vs. Corvus Pharmaceuticals Trevi Therapeutics COMPASS Pathways Aquestive Therapeutics Gossamer Bio Candel Therapeutics Atyr PHARMA Immutep Olema Pharmaceuticals Korro Bio Corvus Pharmaceuticals (NASDAQ:CRVS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, dividends, valuation and risk. Which has higher valuation & earnings, CRVS or PYXS? Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$27.03M-$0.93-4.51Pyxis OncologyN/AN/A-$73.79M-$1.03-1.24 Does the MarketBeat Community prefer CRVS or PYXS? Corvus Pharmaceuticals received 263 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 82.35% of users gave Pyxis Oncology an outperform vote while only 61.91% of users gave Corvus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorvus PharmaceuticalsOutperform Votes29161.91% Underperform Votes17938.09% Pyxis OncologyOutperform Votes2882.35% Underperform Votes617.65% Which has more volatility & risk, CRVS or PYXS? Corvus Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CRVS or PYXS? 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 31.3% of Corvus Pharmaceuticals shares are held by insiders. Comparatively, 9.8% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor CRVS or PYXS? In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 1 mentions for Corvus Pharmaceuticals and 0 mentions for Pyxis Oncology. Corvus Pharmaceuticals' average media sentiment score of 1.66 beat Pyxis Oncology's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Very Positive Pyxis Oncology Neutral Do analysts recommend CRVS or PYXS? Corvus Pharmaceuticals presently has a consensus target price of $12.38, suggesting a potential upside of 195.35%. Pyxis Oncology has a consensus target price of $9.20, suggesting a potential upside of 618.75%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Corvus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Pyxis Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is CRVS or PYXS more profitable? Pyxis Oncology's return on equity of -36.22% beat Corvus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -70.71% -45.90% Pyxis Oncology N/A -36.22%-28.76% SummaryCorvus Pharmaceuticals beats Pyxis Oncology on 10 of the 16 factors compared between the two stocks. Get Pyxis Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for PYXS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYXS vs. The Competition Export to ExcelMetricPyxis OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.12M$7.04B$5.77B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-1.246.1326.4618.82Price / SalesN/A313.76455.0280.40Price / CashN/A67.8344.0437.47Price / Book0.466.747.634.64Net Income-$73.79M$138.11M$3.18B$245.69M7 Day Performance-3.03%-2.43%-1.91%-2.66%1 Month Performance-17.95%-1.91%-0.19%-2.15%1 Year Performance-73.00%-5.03%16.70%12.90% Pyxis Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYXSPyxis Oncology2.0865 of 5 stars$1.28-5.9%$9.20+618.8%-71.6%$76.12MN/A-1.2460CRVSCorvus Pharmaceuticals1.9049 of 5 stars$4.88-0.8%$12.38+153.6%+82.2%$313.59MN/A-5.2530News CoverageTRVITrevi Therapeutics2.7567 of 5 stars$4.07+1.5%$9.31+128.8%+73.6%$312.86MN/A-9.2520News CoveragePositive NewsGap UpCMPSCOMPASS Pathways1.7049 of 5 stars$4.57+3.4%$30.60+569.6%-57.6%$312.68MN/A-2.08120AQSTAquestive Therapeutics2.1557 of 5 stars$3.32-4.3%$11.00+231.3%+19.9%$302.72M$50.58M-7.38160Short Interest ↓Positive NewsGOSSGossamer Bio3.9702 of 5 stars$1.31flat$9.20+602.3%+14.8%$296.85MN/A-4.09180Positive NewsHigh Trading VolumeCADLCandel Therapeutics3.5586 of 5 stars$9.05+2.6%$17.00+87.8%+560.8%$293.91M$120,000.00-5.2360Analyst ForecastNews CoverageATYRAtyr PHARMA2.8189 of 5 stars$3.41-5.0%$19.25+464.5%N/A$286.24M$350,000.00-3.6353Analyst ForecastAnalyst RevisionNews CoverageGap UpIMMPImmutep0.9731 of 5 stars$1.96+0.5%$8.50+333.7%-13.9%$285.30M$5.14M0.002,021Upcoming EarningsOLMAOlema Pharmaceuticals3.2661 of 5 stars$4.97+2.9%$28.75+478.5%-64.0%$284.78MN/A-2.2770KRROKorro Bio0.917 of 5 stars$30.02+3.2%$144.00+379.7%-51.4%$281.29MN/A0.0070News CoverageGap Up Related Companies and Tools Related Companies CRVS Alternatives TRVI Alternatives CMPS Alternatives AQST Alternatives GOSS Alternatives CADL Alternatives ATYR Alternatives IMMP Alternatives OLMA Alternatives KRRO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PYXS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredShocking Elon Move: Bigger than DOGE?After saving free speech with his acquisition of Twitter… And after blowing everyone’s minds with his recen...Brownstone Research | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pyxis Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pyxis Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
